Saturday, February 27, 2010

FDA Approves New Cancer Medication

Patients suffering from kidney cancer received a hopeful boost recently as the U.S.Food and Drug Administration (FDA) approved a new treatment called Votrient (pazopanib).  The drug is approved for patients in advanced renal cell carcinoma, a form of cancer that affects the lining of small tubes within the kidney.

Prior to approval, a study evaluated the efficacy and safety of Votrient by examing 435 patienst who were taking the drub.  Those involved lived an average of 9.2 months post-treatment and those who did not take Votrient lived for 4.2 months.

Cancer of the kidneys unfortunately affects more than 40,000 people every year and the inclusion of Votrient as a viable treatment medication can offer patients another choice to fight the cancer and have more chance for survival.  Taken orally, the drug interferes with angiogensis, the path new vessels undergo that makes it necessary for the growth and survival of tumors.

Although there is much optimism surrouning the approval, patients can have significant side effects when taking the drug, such as:

Vomiting and nausea

Fatigue and weakness

Diarrhea

High blood pressure

Loss of Appetite

Headaches

Arrhythmia irrigularities

Patients who are candidates for Votrient should receive a thorough physical examination by a medical doctor that includes blood and liver function tests due to the fact the drug can cause liver toxicity in some cases.  At that time, the doctor-patient relationship can determine the best course of action.

By providing FDA alerts, interactions and up-to-date drug side effects about prescription and over the counter medications, we can ensure an environment where patients have the best knowledge on their medical treatment and health.

The following post has been written by:

Jesse Herman
Social Media Manager
Drugwatch.com

1 comment:

Whidbey Woman said...

Glad that they are coming out with new treatment options all the time.